U.S. announces pharmaceutical tariffs under Section 232: what it means for biotech compani... 10/04/2026 Healthcare Drug discovery Rare diseases Innovative drugs Industrial biotechnology International At AseBio, we believe this Executive Order creates uncertainty for the European biotechnology sector—especially for... AseBio
AseBio promotes in Brussels the vision of the Spanish biotechnology sector on the Biotech ... 23/03/2026 Healthcare Rare diseases Innovative drugs Advanced therapies EU projects Our Director General, Ion Arocena, participated in the latest meeting of the MEP Interest Group “EU Biotech and Life... AseBio
Sequencing to diagnose earlier: how biotechnology can help short the rare diseases diagnos... 28/02/2026 Healthcare Rare diseases In a context in which most of these pathologies have a genetic origin, tools such as whole genome sequencing (WGS) are... Partners - Illumina
WORLD Orphan Drug Congress USA Boston USA Del 10/06/2026 to 11/06/2026 Access to innovation Rare diseases
AseBio welcomes the European institutions’ decision to move forward with the EU pharmaceut... 17/12/2025 Healthcare Drug discovery Rare diseases Innovative drugs Advanced therapies Antibiotic resistance As this legislation has not been amended for more than two decades, we encourage the Commission to be more ambitious in... AseBio
ORYZON awarded 13.26 million € through the first Important Project of Common European Inte... 08/05/2025 Healthcare Rare diseases Innovative drugs Oryzon to validate epigenetic agents by applying a personalized medicine approach for rare and orphan diseases. Partners - Oryzon Genomics
Nuage Therapeutics, Ona Therapeutics, and SpliceBio are leading the wave of biotech innova... 05/05/2025 Healthcare Rare diseases Personalized medicine Advanced therapies Las biotecnológicas Nuage Therapeutics, Ona Therapeutics y SpliceBio, con sede en el Parque Científico de Barcelona, han... Partners - Parc Científic de Barcelona
Biotechnology opens the door to gene therapies for rare diseases 27/02/2025 Healthcare Rare diseases Despite advances in biotechnology and research, the lack of specialists, scarcity of treatments, and inequality in... AseBio
Leriglitazone has met the primary endpoint in NEXUS, the pivotal trial for pediatric pati... 11/12/2024 Healthcare Rare diseases Statistically significant difference in arrested disease in leriglitazone treated patients when compared to the natural... Partners - Minoryx Therapeutics
Rare Disease Summit Philadelphia USA Del 18/03/2025 to 20/03/2025 Healthcare Rare diseases International
